# ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2

> **NIH NIH N01** · MEABCO INC · 2021 · $2,033,102

## Abstract

The company plans to obtain FDA approval for BP-C2, a lignin-derived polyphenolic complex with ammonium molybdate, as a topical and/or oral treatment against injuries associated with cutaneous radiation syndrome.

## Key facts

- **NIH application ID:** 10400553
- **Project number:** 75N93020C00004-P00005-9999-1
- **Recipient organization:** MEABCO INC
- **Principal Investigator:** SERGEI PIGAREV
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,033,102
- **Award type:** —
- **Project period:** 2020-05-01 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10400553

## Citation

> US National Institutes of Health, RePORTER application 10400553, ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2 (75N93020C00004-P00005-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10400553. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*